



Since the human papillomavirus (HPV) vaccine guidelines were developed by the Korean 
Society of Gynecologic Oncology (KSGO) in 2011, 2016, and 2019, several recent studies 
on the efficacy and safety of HPV vaccines in middle-aged women and men have been 
reported. Furthermore, there has been an ongoing debate regarding the efficacy of the HPV 
vaccine in women with prior HPV infection or who have undergone conization for cervical 
intraepithelial neoplasia (CIN). We searched and reviewed studies on the efficacy and safety 
of the HPV vaccine in middle-aged women and men and the efficacy of the HPV vaccine in 
patients infected with HPV and those who underwent conization for CIN. The KSGO updated 
their guidelines based on the results of the studies included in this review.
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High-risk human papillomavirus (HPV) infection is associated with the incidence of cervical, 
vaginal, vulvar, penile, anal, and oropharyngeal cancers and is responsible for 5%–10% of all 
cancers [1]. In particular, cervical cancer accounts for 80% of HPV-related cancers [2]. HPV 
is the most widespread sexually transmitted infection, with a prevalence of approximately 
11%, and persistent HPV infection is a major cause of cervical precancerous lesions and 
cancer [3,4]. Prophylactic vaccination against high-risk HPV can prevent precancerous 
lesions of cervical cancer and cervical cancer, as well as cancers that occur in men, such as 
oropharyngeal cancer, anal cancer, and penile cancer [5-8].
To date, three HPV vaccines have been approved; they can prevent infection with HPV types 
16 and 18, which cause approximately 70% of cervical cancers and other HPV-related tumors 
[6,9-16]. The quadrivalent vaccine can further prevent infection with HPV types 6 and 11, 
which account for 90% of genital warts [17]. The most recently introduced 9-valent vaccine 
can protect against infection with 5 additional types of high-risk HPV (31, 33, 45, 52, and 58), 
in addition to these 4 types of HPV [18].
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1.  Key question 1: what is the recommended age for the 3-dose schedule of the HPV 
vaccine?
•  The optimal age for the 3-dose schedule of the quadrivalent HPV vaccine is 9–45 
years in girls and women and 9–26 years in boys and men (IA).
•  The optimal age for the three-dose schedule of the bivalent HPV vaccine is 9–45 
years in girls and women (IA) and 9–25 years in boys and men (IIC).
•  The optimal age for the three-dose schedule of the nonavalent HPV vaccine is 9–45 
years in girls and women and 9–26 years in boys and men (girls and women aged 
9–26 years, IA; women aged 27–45 years, IIIB; and boys and men aged 9–26 years, IA).
2. Key question 2: is the HPV vaccine effective in women already infected with HPV?
•  In HPV-infected women already, the administration of the quadrivalent HPV vaccine 
can lower the risk of infection with an uninfected HPV subtype (IIB).
•  In HPV-infected women already, the administration of the bivalent HPV vaccine can 
lower the risk of infection with an uninfected HPV subtype (IIB).
•  In HPV-infected women already, the administration of the nonavalent HPV vaccine 
can lower the risk of infection with an uninfected HPV subtype (IIB).
3.  Key question 3: is the HPV vaccine effective in preventing the recurrence of HPV-
related diseases in patients who underwent conization?
•  In women who underwent conization, the administration of the quadrivalent HPV 
vaccine can reduce the risk of recurrence of HPV-related diseases by preventing 
infection with the corresponding viral subtype (IIB).
•  In women who underwent conization, the administration of the bivalent HPV 
vaccine can reduce the risk of recurrence of HPV-related diseases by preventing 
infection with the corresponding viral subtype (IIB).
•  In women who underwent conization, the administration of the nonavalent HPV 
vaccine can reduce the risk of recurrence of HPV-related diseases by preventing 
infection with the corresponding viral subtype (IVB).
The Korean Society of Gynecologic Oncology (KSGO) provided and updated the 
clinical recommendations for HPV vaccines in 2011 and 2016 [19,20] and announced a 
recommendation for the 9-valent HPV vaccine in 2019 [8].
However, many studies have been recently reported on the effectiveness of HPV vaccines in 
middle-aged women and men. Additionally, the effectiveness of HPV vaccines in women 
already infected with HPV or who have undergone conization for precancerous cervical 
lesions is controversial. Therefore, updated recommendations for HPV vaccines are required.
METHODS
1. Developing the recommendations for HPV vaccine
The key questions and scope of guideline were derived through a meeting of the committee. 
The committee tried to develop a guideline by systematically searching for the latest literature 
related to vaccines and evaluating evidence.
2. Strategy of literature search
According to the criteria for selection and exclusion criteria of all key questions, 2 reviewers 
per document independently selected and excluded the literature. The primary selection 
and exclusion were made by looking at the title and the abstract, and the literature selected 
by even 1 reviewer was searched for the original article. After that, the committee members 
selected and excluded based on the original article, and if there was no agreement between 
the members, the final selection and exclusion was decided through discussion. Articles were 
searched on Ovid-MEDLINE, Ovid-Embase, and Cochrane Library.
3. Quality assessment of literature
In the selected literature, randomized controlled clinical researches were evaluated using 
risk of bias (ROB) of Cochrane, and non-randomized observational studies were assessed 
by NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES. The quality 
of the literature is assessed independently by 2 members, and it was determined by an 
agreement between the 2 members if the quality of the literature is different.
4. Summary of evidence and data extraction
Data extraction from the final selected literature was carried out independently by 2 working-
level members according to the predetermined data extraction form. If data extracted were 
different between the 2 members, final settlement was made by discussion. A summary of 
evidence is attached to the Data S2. Classification of evidence and recommendations are 
displayed in Tables 1 and 2.
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Table 1. Level of evidence
Level Type of evidence
I RCTs, or overwhelming evidence from observational studies
II RCTs with important limitations, or exceptionally strong evidence from observational studies
III Observational studies, or RCTs with notable limitations
IV Clinical experience and observations, observational studies with important limitations, or RCTs with 
several major limitations
V No evidence or difficult to analysis or based on expert opinion
RCT, randomized controlled trial.
EVIDENCE OF HPV VACCINES
The process of developing clinical guidelines and an evidence table for each key question is 
addressed in the Supplementary Materials (Data S1 and S2).
1.  Key question 1: what is the recommended age for receiving the HPV vaccine 
via a 3-dose schedule?
In 2016, the KSGO recommended 9–26 years of age as the appropriate age for receiving the 
three doses of the 4-valent vaccine and 9–25 years of age as the appropriate age for receiving 
the three doses of the 2-valent vaccine in girls and women [21]. Additionally, in 2019, girls 
and women aged 9–26 years were recommended as appropriate for receiving the three doses 
of the 9-valent vaccine [8]. In this guideline, the effectiveness and safety of the three doses of 
the HPV vaccine in middle-aged women and men have been investigated.
The quadrivalent HPV vaccine
To date, 2 randomized controlled trials (RCTs) for women over 20 years of age have been 
published, and 5 papers have been identified. [22-26]. In a multinational clinical trial 
published in 2009 (Protocol 019, NCT00090220), an interim analysis was performed 
in women aged 24–45 years over an average follow-up period of 2.2 years. The vaccine's 
efficacies against infection or disease associated with 4 types of HPV (6, 11, 16, and 18) and 
2 types of HPV (16 and 18) were 90.5% (95% confidence interval [CI]=73.7, 97.5) and 83.1% 
(95% CI=50.6, 95.8), respectively [22]. After 4 years of follow-up, the efficacies against 
diseases related to the 4 types of HPV were 88.7% (95% CI=78.1, 94.8), and 66.9% (95% 
CI=4.3, 90.6) in women who were not infected with the 4 types of HPV and those who were 
vaccinated at least once, respectively [23]. The seropositivity rates for antibodies against HPV 
types 6, 11, 16, and 18 at 48 months after the first vaccination were 91.5%, 92.0%, 97.4%, and 
47.9%, respectively, and no serious side effects were reported [22,23].
In the study V501-041 (NCT00834106), the vaccine's efficacy against cervical intraepithelial 
neoplasia (CIN) ≥2 related to HPV types 16 and 18 over a 78-month follow-up period in 
Chinese women aged 20–45 years was 100% (95% CI=32.3, 100) and that against CIN grade 
1+ related to HPV types 6, 11, 16 and 18 was also 100% (95% CI=70.9, 100). Additionally, its 
efficacy against persistent infection with HPV types 16 and 18 was 97.5% (95% CI=85.1, 99.9), 
and the efficacy against abnormal cytology related to HPV types 6, 11, 16, and 18 was 94.0% 
(95% CI=81.5, 98.8) [26]. No serious adverse reactions were observed [25].
An RCT involving adolescent male aged 9–15 years and 2 RCTs involving male participants 
aged 16–26 years have been published. In V501-018 (NCT00092547), the seropositivity rate in 
adolescent boys aged 9–15 years at 10 years after vaccination was 89.96%, and the antibody titer 
was 16%–42% higher in boys aged 9–12 years than in boys aged 13–15 years [5]. In the Merck 
protocol 020 trial (NCT00090285) for boys and men aged 16–26 years, the vaccine's efficacies 
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Table 2. Grade of recommendations
Grade Descriptor
A Strongly recommended, strong evidence
B Generally recommended, moderate evidence
C Optional, insufficient evidence
D Generally not recommended
E Never recommended
against anal epithelial neoplasia related to HPV types 6, 11, 16, and 18 after a follow-up period of 
2.2 years were 77.5% (95% CI=39.6, 93.3) and 50.3% (95% CI=25.7, 67.2) in the per protocol and 
intention to treat populations, respectively. Additionally, the incidence of anal intraepithelial 
neoplasia 2 and 3 in men who received the vaccine decreased by 74.9% (95% CI=8.8, 95.4) and 
54.2% (95% CI=18.0, 75.3) in the per protocol and intention to treat populations, respectively 
[27]. In phase II study for boys and men aged 16–26 years, the vaccine's efficacies against 
external genital warts were 90.4% (95% CI=69.2, 98.1) and 65.5% (95% CI=45.8, 78.6) in the 
per protocol and intention to treatment populations, respectively [6].
For the 4-valent vaccine, 2 doses were recommended from the age of 9 to 13 years, based on 
previous studies (level of evidence I, recommendation level B).
The above results determined the following recommendation for target of quadrivalent HPV 
vaccine:
The bivalent HPV vaccine
Three RCTs [28-30] and three observation studies [31-33] on middle-aged women were 
identified. A RCT (VIVIANE study, NCT00294047) in women over 25 years of age evaluated 
and compared the efficacy of the vaccine in the following age groups: 26–35, 36–45, and 
46–55 years [30]. The efficacy of the 2-valent vaccine against 6-month-long infection or mild 
cervical epithelial dysplasia associated with HPV types 16 or 18 was 81.1% (97.7% CI=52.1, 
94.0) in all age groups, 83.5% (97.7% CI=45.0, 96.8) in the 26–35 years age group, and 77.2% 
(97.7% CI=2.8, 96.9) in the 36–45 years age group. In an RCT (study HPV-010, NCT00423046) 
comparing the 2-valent and 4-valent vaccines in women aged 18–45 years, the seropositivity 
rate for HPV type 16 at 60 months after vaccination was 100% in the 2-valent vaccine group 
and 97.5–100% in the 4-valent vaccine group. The seropositivity rate for HPV type 18 was 
99.0–100% in the 2-valent vaccine group and 72.3%–84.4% in the 4-valent vaccine group 
[29]. However, the antibody titer and the duration of antibody production against HPV type 
16 or 18 were found to decrease in women aged 27–35 years and 36–45 years compared with 
that in women aged 18–26 years (HPV 16 and 18: women aged 18–26 years, 68.2 and 40.6 
years, respectively; women aged 27–35 years, 57.3 and 9.5 years, respectively; and women aged 
36–45 years, 31.0 and 1.9 years, respectively). No serious adverse effects were observed. In 
men, a phase I/II RCT was noted [7]. Seven months after vaccination in boys aged 10–18 years, 
seropositivity was 100%, and no serious side effects were observed. Additionally, for the 
2-valent vaccine, the 2 doses were recommended at the age of 9–14 years based on previous 
research outcomes, including those from RCTs, and the 2016 KSGO recommendation (level 
of evidence I, recommendation level B).
According to the aforementioned results, the recommendation was as follows:
5/13https://ejgo.org https://doi.org/10.3802/jgo.2021.32.e94
KSGO guideline for HPV vaccine
•  The optimal age for the 3-dose schedule of the 4-valent HPV vaccine is 9–45 years in 
girls and women and 9–26 years in boys and men (IA).
•  The optimal age for the three-dose schedule of the 2-valent HPV vaccine is 9–45 years 
in girls and women (IA) and 9–25 years in boys and men (IIC).
The nonavalent vaccine
A recently published phase III RCT (NCT03158220) that evaluated the efficacy and safety of 
the 9-valent vaccine was identified [34]. In this RCT, the immunogenicity and stability of the 
9-valent vaccine were evaluated in women aged 27–45 years compared with those in women 
aged 16–26 years. At 7 months of vaccination, antibody titers against HPV types 6, 11, 16, 18, 
31, 33, 45, 52, and 58 were not significantly different between women aged 27–45 years and 
women aged 16–26 years (0.60–0.67). The seroconversion rate was 99% or higher for all HPV 
types. No serious vaccine-related side effects have been reported to date. In boys and men, in 
the recommendations published in 2019 by the KSGO the 9-valent vaccine was recommended 
for boys and men aged 9–26 years (level of evidence I, recommendation level A) [8].
Based on this information, the recommendations was as follows:
2.  Key question 2: is the HPV vaccine effective in women already infected 
with HPV?
The quadrivalent HPV vaccine
In a randomized pilot study, 10 women aged 27–45 years who tested positive for HPV 16 were 
divided into the vaccinated and non-vaccinated groups. In the vaccination group, antibody 
titers increased by 24–930-fold, and the number of memory B cells increased by 3–27-fold [35].
Based on the above results, the following was recommended:
The bivalent vaccine
A phase III RCT (PATRICIA study, NCT00122681) in girls and women aged 15–25 years was 
identified. According to this study, when the 2-valent HPV vaccine was administered to 
women infected with HPV type 16 or 18 at the beginning of the study, the efficacy against CIN 
grade 2+ related to an HPV type other than the one causing infection was 90% (95% CI=31.8, 
99.8) [36].
Based on the above results, the recommendation was as follows:
The nonavalent vaccine
A combined study of three RCTs (9-valent Vaccine Study Protocol V503-001, Quaternary 
Vaccine Study Protocol V501-013, and V501-015) was identified. In this study, the incidence of 
cervical lesion related to HPV 31, 33, 45, 52, and 58 was decreased among women who tested 
positive at baseline for HPV 6, 11, 16, or 18 but tested negative for HPV 31, 33, 45, 52, and 58 
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•  The optimal age for the three-dose schedule of the 9-valent HPV vaccine is 9–45 years 
in girls and women and 9–26 years in boys and men (girls and women aged 9–26 years, 
IA; women aged 27–45 years, IIIB; and boys and men aged 9–26 years, IA).
•  In HPV-infected women already, the administration of the quadrivalent HPV vaccine 
can lower the risk of infection with an uninfected HPV subtype (IIB).
•  In HPV-infected women already, the administration of the bivalent HPV vaccine can 
lower the risk of infection with an uninfected HPV subtype (IIB).
(all grades: 95.1%; high grades: 91.1%). Similarly, in women who tested positive at baseline 
for HPV 31, 33, 45, or 52 but tested negative for HPV 6, 11, 16, and 18, the incidence of cervical 
disease related to HPV 6, 11, 16, and 18 was also significantly reduced (all grades: 97.4%; high 
grade: 95.8%) [12].
Based on the above results, the recommendation was as follows:
3.  Key question 3: is the HPV vaccine effective in preventing the recurrence of 
HPV-related diseases in patients who have undergone conization?
The quadrivalent vaccine
In an RCT of 312 patients who received treatment such as conization for CIN grade 1–3, the 
recurrence rate of CIN grade 1–3 was significantly decreased (58.7%) in the vaccinated group 
compared with that in the control group [37]. In a prospective case-control study of patients 
who underwent cone resection for CIN, the risk of high-grade cervical epithelial tumors in 
vaccinated patients was reduced by 81.2% (95% CI=34.3, 95.7) [38]. In a retrospective study 
of 20–45-year-old Korean women who underwent cone resection for high-grade CIN, the 
recurrence rate of high-grade CIN was decreased in the vaccinated group (vaccinated group, 
2.5%; unvaccinated group, 7.2%), and the recurrence risk of high-grade CIN was significantly 
higher in the unvaccinated group than in the vaccinated group (hazard ratio=2.84; 95% 
CI=1.335, 6.042) [39]. In a single-center retrospective study of women who underwent 
conization for cervical dysplasia, the recurrence of cervical dysplasia was less common in the 
vaccinated group than in the unvaccinated group (7.1% vs. 16.5%, p=0.02), and vaccination 
after conization was a significant factor in preventing recurrence (odds ratio [OR]=0.2; 95% 
CI=0.1, 0.6) [40].
Based on the above, the following was recommended:
The bivalent vaccine
In an RCT (PATRICIA, NCT00122681) including girls and women aged 15–25 years, vaccine 
efficacy against the recurrence of CIN grade ≥2 was 88.2% (95% CI=14.8, 99.7) in women who 
underwent conization after vaccination [41]. However, in a analysis of RCT (Costa Rica HPV 
Vaccine Trial, NCT00128661), no vaccine efficacy was noted against cervical precancerous 
lesions in patients who underwent conization for cervical lesions after vaccination (efficacy: 
high-grade squamous intraepithelial lesion + −163.3% [95% CI= −742, 18]; CIN2+ −55.5% 
[95% CI=−834, 74]) [42]. In a meta-analysis that included the above 2 studies (2 studies on 
the 2-valent vaccine and three studies on the 4-valent vaccine), vaccination before and after 
conization could reduce the recurrence of CIN grade ≥2 (pretreatment vaccination: OR=0.4; 
95% CI=0.21, 0.78; post-treatment vaccination: OR=0.28; 95% CI=0.14, 0.56) [43].
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•  In HPV-infected women already, the administration of the nonavalent HPV vaccine can 
lower the risk of infection with an uninfected HPV subtype (IIB).
•  In women who underwent conization, the administration of the quadrivalent HPV 
vaccine can reduce the risk of recurrence of HPV-related diseases by preventing 
infection with the corresponding viral subtype (IIB).
Based on the above results, the following recommendations were made:
The nonavalent vaccine
In a retrospective study of women who were vaccinated after conization (2-valent: 19.6%; 
4-valent: 4.6%; 9-valent: 64.1%), the incidence of persistent or recurrent high-grade CIN was 
significantly lower in the vaccinated group than in the unvaccinated group (3.3% vs. 10.7%, 
p=0.015), and the risk of persistent or recurrent high-grade CIN was significantly decreased 
in the vaccinated group (OR=0.2; 95% CI=0.1, 0.7) [44].
Based on the above results, the following was recommended:
DISCUSSION
The presented recommendations are based on evidence but have several controversial 
aspects. Although this guideline recommends HPV vaccination in middle-aged women, the 
optimal age for vaccination is between 9 and 26 years in girls and women. In women aged 
27–45 years, vaccination safety has been sufficiently proven, but the vaccine may be less 
effective because these women may have already been exposed to the virus [45]. In addition, 
because only one RCT has been performed for the 9-valent vaccine in middle-aged women, 
the evidence is insufficient for this vaccine. Therefore, doctors should fully discuss the 
benefits of vaccination with the patient prior to vaccination. Moreover, further research is 
required to identify middle-aged women who can benefit from vaccination and to study the 
cost-effectiveness of vaccination in this population.
HPV vaccines are administered via a 2-dose schedule for most persons who initiate 
vaccination at 9–14 years of age. Based on several RCTs, 2 doses of the 4-valent and 2-valent 
vaccines are recommended for boys and girls aged 9–13 years and 9–14 years, respectively 
[21,46,47].
This guideline recommends a 2-valent vaccine for boys and men aged 9–25 years. However, 
only one phase I/II randomized study has evaluated immunogenicity in boys aged 10–18 years 
[7]. Owing to insufficient evidence, further studies on 2-valent HPV vaccines in adolescent 
boys and young adult men are required.
These guidelines recommend that the administration of the HPV vaccine can lower the 
risk of infection with an HPV subtype other than the ones causing the infection in women 
already infected with HPV. This must be interpreted carefully, as it can be misunderstood 
as the vaccine leading to HPV clearance in women after infection. Clinical studies have 
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•  In women who underwent conization, the administration of the bivalent HPV vaccine 
can reduce the risk of recurrence of HPV-related diseases by preventing infection with 
the corresponding viral subtype (IIB).
•  In women who underwent conization, the administration of the nonavalent HPV 
vaccine can reduce the risk of recurrence of HPV-related diseases by preventing 
infection with the corresponding viral subtype (IVB).
demonstrated that vaccination does not eliminate HPV already present in women [12,35,36]. 
In addition, evidence to support the effectiveness of vaccination in patients who have already 
undergone conization is still inconclusive. In a analysis study of an RCT, no vaccine efficacy 
was observed against cervical precancerous lesions in patients who underwent conization for 
cervical lesions after vaccination [42]. Although recent meta-analysis shows a significant risk 
reduction of recurrence or persistence of CIN2+ after conization [43,48,49], well-designed 
RCTs are needed in future.
Regarding the safety of the HPV vaccine, no associations with multiple sclerosis, other 
disorders of the central nervous system, demyelinating disorders, Guillain-Barré syndrome, 
neurological diseases, venous thromboembolism, and autoimmune diseases have been 
revealed in observational studies and randomized clinical studies [50-53]. In addition, 
in a recently published registry-based study on 11–14-year-old Korean girls, 33 serious 
complications, including Hashimoto's thyroiditis, rheumatoid arthritis, and malignant 
headache, were demonstrated to not be associated with HPV vaccination [54].
The present recommendation requires further updates based on further research on men and 
middle-aged women or on controversial aspects.
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